Biomaterial Database

Radiofrequency ablation of hepatocellular carcinoma: predicting success using contrast-enhanced sonography. 2006

Marcus J Dill-Macky, and Murray Asch, and Peter Burns, and Stephanie Wilson

Department of Medical Imaging, University Health Network/Mount Sinai Hospital, Toronto, Ontario, Canada. Mrcus.Dill-Macky@uhn.on.ca

OBJECTIVE This pilot study compared the utility of immediate postprocedural contrast-enhanced sonography with that of delayed enhanced sonography and CT or MRI in assessing the success of radiofrequency ablation of hepatocellular carcinoma. METHODS Twenty-two lesions (1.5-3.7 cm) were studied in 19 patients. Enhanced sonography was performed before and within 1 hr after radiofrequency ablation. At routine 2-week follow-up CT or MRI, additional enhanced sonography was performed. The findings of preablation CT or MRI and enhanced sonography were compared with those of postprocedural and follow-up enhanced sonography by three radiologists experienced in these techniques. The reviewers were unaware of the follow-up CT or MRI results (reference standard). Technical adequacy, ablation zone targeting, and identification of residual disease were assessed by each reviewer, and the results were analyzed by consensus. RESULTS One postprocedural sonographic study was considered technically inadequate. Postprocedural sonography predicted the follow-up CT or MRI results in 76% (16/21) of subjects (sensitivity, 88%; specificity, 40%; positive predictive value [PPV], 82%; negative predictive value, [NPV] 50%). Follow-up CT or MRI identified accurate targeting in 17 of 22 subjects. Follow-up sonography agreed with CT or MRI in 82% (18/22) of subjects (sensitivity, 88%; specificity, 67%; PPV, 88%; NPV, 67%). Postprocedural sonography predicted the follow-up CT or MRI results in 81% (17/21) of subjects (sensitivity, 40%; specificity, 94%; PPV, 66%; NPV, 83%). Follow-up CT or MRI detected residual disease in six subjects. Follow-up sonography agreed with CT or MRI in 91% (20/22) of subjects (sensitivity, 83%; specificity, 94%; PPV, 83%; NPV, 94%). CONCLUSIONS Postprocedural enhanced sonography has the potential to guide completion of radiofrequency ablation at the time of initial therapy when residual disease is detected. The procedure is less accurate in detection of residual disease than is either delayed enhanced sonography or CT or MRI.

UI	MeSH Term	Description	Entries
D008113	Liver Neoplasms	Tumors or cancer of the LIVER.	Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008279	Magnetic Resonance Imaging	Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.	Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D010865	Pilot Projects	Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.	Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D011237	Predictive Value of Tests	In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.	Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D012074	Remission Induction	Therapeutic act or process that initiates a response to a complete or partial remission level.	Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D005260	Female		Females
D006528	Carcinoma, Hepatocellular	A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man